3-methyl-1-(4-methylpyridin-3-yl)butan-1-one | 435273-41-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3-methyl-1-(4-methylpyridin-3-yl)butan-1-one
• CAS: 435273-41-9
• 化学式: C₁₁H₁₅NO
• 分子量: 177.246
• InChiKey: BJUUQJJXYSGLAD-UHFFFAOYSA-N

物化性质

• 沸点：
  286.4±20.0 °C(Predicted)
• 密度：
  0.982±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  30
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-methyl-1-(4-methylpyridin-3-yl)butan-1-one 、 溴 以the title compound (3.69 g) was obtained as a pale-yellow powder的产率得到2-Bromo-3-methyl-1-(4-methylpyridin-3-yl)butan-1-one
  参考文献：
  名称：

  Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof

  摘要：

  本发明提供了一种具有类固醇C17,20-裂解酶抑制活性的药物组合物，可用作前列腺增生症、乳腺癌等肿瘤的预防或治疗剂，更具体地说，是一种含有以下化合物的类固醇C17,20-裂解酶抑制剂：其中A1是一个芳香族碳氢基团，可选地具有取代基或一个杂环基团，A2和A3中的一个是氢原子、卤素原子、可选地具有取代基的C1-4脂肪烃基团或可选地酯化的羧基团，另一个是可选地具有取代基的芳香族碳氢基团或杂环基团，而A1、A2和A3中的至少一个是可选地具有取代基的3-吡啶基团，或其盐或前药。

  公开号：

  US07067537B2
• 作为产物：
  描述：

  3-氰基-4-甲基吡啶 、 ISOBUTYLMAGNESIUM BROMIDE 在 盐酸 、 水 作用下， 以 乙醚 为溶剂， 反应 26.0h， 生成 3-methyl-1-(4-methylpyridin-3-yl)butan-1-one
  参考文献：
  名称：

  SUBSTITUTED THIAZOLE DERIVATIVES BEARING 3-PYRIDYL GROUPS, PROCESS FOR PREPARING THE SAME AND USE THEREOF

  摘要：

  公开号：

  EP1348706B1

文献信息

• A Novel Small-Molecule Inhibitor of SREBP-1 Based on Natural Product Monomers Upregulates the Sensitivity of Lung Squamous Cell Carcinoma Cells to Antitumor Drugs
  作者：De-Bin Ma、Xing-Yu Liu、Hui Jia、Yingshi Zhang、Qiyu Jiang、Huiwei Sun、Xiaojuan Li、Fang Sun、Yantao Chai、Fan Feng、Lei Liu

  DOI：10.3389/fphar.2022.895744

  日期：——

  The transcription factor, sterol regulatory element binding protein 1 (SREBP-1), plays important roles in modulating the proliferation, metastasis, or resistance to antitumor agents by promoting cellular lipid metabolism and related cellular glucose-uptake/Warburg Effect. However, the underlying mechanism of SREBP-1 regulating the proliferation or drug-resistance in lung squamous cell carcinoma (LUSC) and the therapeutic strategies targeted to SREBP-1 in LUSC remain unclear. In this study, SREBP-1 was highly expressed in LUSC tissues, compared with the paired non-tumor tissues (the para-tumor tissues). A novel small-molecule inhibitor of SREBP-1, MSI-1 (Ma’s inhibitor of SREBP-1), based on natural product monomers, was identified by screening the database of natural products. Treatment with MSI-1 suppressed the activation of SREBP-1-related pathways and the Warburg effect of LUSC cells, as indicated by decreased glucose uptake or glycolysis. Moreover, treatment of MSI-1 enhanced the sensitivity of LUSC cells to antitumor agents. The specificity of MSI-1 on SREBP-1 was confirmed by molecular docking and point-mutation of SPEBP-1. Therefore, MSI-1 improved our understanding of SREBP-1 and provided additional options for the treatment of LUSC.

  转录因子固醇调节元件结合蛋白1（SREBP-1）通过促进细胞脂质代谢和相关的细胞葡萄糖摄取/沃伯格效应，在调节细胞增殖、转移或对抗肿瘤药物的耐药性方面发挥着重要作用。然而，SREBP-1调节肺鳞状细胞癌（LUSC）增殖或耐药性的潜在机制以及针对SREBP-1的治疗策略仍不清楚。本研究发现，与配对的非肿瘤组织（准肿瘤组织）相比，SREBP-1在LUSC组织中高表达。通过筛选天然产物数据库，发现了一种基于天然产物单体的新型小分子SREBP-1抑制剂MSI-1（Ma's inhibitor of SREBP-1）。MSI-1抑制了SREBP-1相关通路的激活和LUSC细胞的沃伯格效应，表现为葡萄糖摄取或糖酵解的减少。此外，MSI-1还提高了LUSC细胞对抗肿瘤药物的敏感性。分子对接和SPEBP-1的点突变证实了MSI-1对SREBP-1的特异性。因此，MSI-1增进了我们对SREBP-1的了解，为治疗LUSC提供了更多选择。
• US7067537B2
  申请人：——

  公开号：US7067537B2

  公开（公告）日：2006-06-27
• SUBSTITUTED THIAZOLE DERIVATIVES BEARING 3-PYRIDYL GROUPS, PROCESS FOR PREPARING THE SAME AND USE THEREOF
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP1348706B1

  公开（公告）日：2009-08-19
• Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof
  申请人：——

  公开号：US20040072876A1

  公开（公告）日：2004-04-15

  The present invention provides a pharmaceutical composition having a steroid C 17,20 -lyase inhibitory activity, which is useful as a prophylactic or therapeutic agent of prostatism, tumor such as breast cancer and the like, more particularly, a steroid C 17,20 -lyase inhibitor containing a compound represented by the formula: 1 wherein A 1 is an aromatic hydrocarbon group optionally having substituents or a heterocyclic group optionally having substituents, one of A 2 and A 3 is a hydrogen atom, a halogen atom, a C 1-4 aliphatic hydrocarbon group optionally having substituents or an optionally esterified carboxyl group, the other of A 2 and A 3 is an aromatic hydrocarbon group optionally having substituents or a heterocyclic group optionally having substituents, and at least one of A 1 , A 2 and A 3 is a 3-pyridyl group optionally having substituents, or a salt thereof or a prodrug thereof.

  本发明提供了一种具有类固醇C17,20-裂解酶抑制活性的药物组合物，其可作为前列腺增生症、乳腺癌等肿瘤的预防或治疗剂，更具体地，是一种含有以下化合物的类固醇C17,20-裂解酶抑制剂：式中，A1为芳香族碳氢基团，可选地具有取代基，或者为杂环基团，可选地具有取代基；A2和A3中的一个为氢原子、卤素原子、C1-4脂肪族碳氢基团，可选地具有取代基，或者为可选酯化的羧基；另一个为芳香族碳氢基团，可选地具有取代基，或者为杂环基团，可选地具有取代基；且A1、A2和A3中至少有一个为可选地具有取代基的3-吡啶基团，或其盐或前药。